About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.

Cardiovascular Risk Factors, Aging and Dementia

Clinicaltrials.gov identifier NCT03938727

Recruitment Status Recruiting

First Posted May 6, 2019

Last update posted September 6, 2019

Study Description

Brief summary:

The global challenges caused by dementia affect society from both the public health and economic perspective, and are exacerbated by the rapid growth of the population in the oldest age groups. Reducing the risk of developing dementia and improving the overall health status, psychosocial wellbeing, and the quality of life of the oldest old would bear individual and public health benefits, as well as social and economic advantages. Data from long-term longitudinal cohort studies can provide invaluable information about the factors that play a key role in healthy ageing and in the development of dementia. The aim of CAIDE 85+ is to better understand the factors that, from mid- to late-life, determine the development of cognitive disorders such as dementia, as well as the overall health status, psychosocial wellbeing and quality of life in the oldest old segment of the population. CAIDE85+ is the third follow-up of the main Cardiovascular Risk Factors, Aging and Dementia (CAIDE) study conducted in the Kuopio and Joensuu areas in Eastern Finland. During midlife, participants were initially part of two population-based health surveys (North Karelia project and FINMONICA study) carried out between 1972 and 1987. In 1998, a random sample of 2000 individuals (aged 64-79) from these cohorts were invited to participate in a first re-examination as part of the CAIDE study. A second re-examination of this population was carried out between 2005 and 2008. Individuals who are still alive and living in the Kuopio and Joensuu areas will now be invited for a third re-examination. Participants' cognitive functioning and physical fitness will be assessed, and they will be asked questions about their health status, psychosocial wellbeing, and lifestyle. Blood samples will be also collected to investigate biomarkers that may be relevant for dementia-related diseases.

  • Condition or Disease:Dementia
  • Intervention/Treatment:
  • Phase: N/A
Detailed Description

The Cardiovascular Risk Factors, Aging and Dementia (CAIDE) study was initiated in 1998 with the main scope of investigating the potential role of modifiable risk and protective factors in the development of dementia. 2000 people, who, in mid-life between 1972 and 1987, had taken part in the North Karelia, and FINMONICA survey studies, were invited to participate. These previous cohort studies focused mostly on cardiovascular disease and related risk factors and provided baseline data for the CAIDE study. Within CAIDE, two follow-ups have been carried out so far, the first in 1998 and the second between 2005 and 2008, on average 21 and more than 30 years after the baseline studies, respectively. The CAIDE study has, so far, provided essential knowledge on several midlife risk and protective factors for dementia, including interactions between genetics and lifestyle. In addition, the CAIDE Dementia Risk Score was developed as the first tool for predicting the risk of late-life dementia in middle-aged people, based on their lifestyle and cardiovascular risk profiles. Ten years after the second re-examination, the CAIDE participants are now well in their middle 80s' or older. Despite being the fastest growing segment of the population, this age group has been only rarely the subject of similar observational studies. By investigating the health status, quality of life, and overall psycho-physical functionality in this population the investigators aim to further examine risk and protective factors for dementia. To this aim, a life-course approach will be applied on a unique longitudinal population-based dataset spanning over 40 years, a very long period of time that is rarely achievable in observational studies. The results will also provide insights on the predictors and determinants of quality of life and psychosocial wellbeing in the oldest old. CAIDE85+ is the third follow-up of the main CAIDE study. At baseline (midlife), data on e.g. socio-demographics, lifestyle, anthropometric measurements, blood pressure, blood markers, and medical history were recorded. In addition, the first and second late-life re-examinations included cognitive assessments (three-step protocol for the diagnosis of Mild Cognitive Impairment and dementia), APOEƐ4 genotyping, and more detailed data on psychosocial factors, and medication use. In principle, the same measurements and methods will be used in CAIDE 85+, except for modifications/adaptations required by the specifics of the 85+ study population, or recent scientific developments related to the aims of the study. New developments compared with previous re-examinations include e.g. single-step assessment of cognitive status for all participants; more detailed assessment of physical functioning, multimorbidity and frailty; inclusion of questionnaires on oral health, sleep quality, malnutrition, and health-related quality of life. Potential participants will be identified within the original CAIDE cohort, i.e. individuals who are still alive and living in the area where the study takes place (Kuopio and Joensuu, Finland).

Study Design
  • Study Type: Observational
  • Estimated Enrollment: 500 participants
  • Observational Model: Cohort
  • Time Perspective: Prospective
  • Official Title: Cardiovascular Risk Factors, Aging and Dementia (III Follow-up)
  • Actual Study Start Date: June 2019
  • Estimated Primary Completion Date: December 2020
  • Estimated Study Completion Date: December 2020
Outcome Measures
  • Primary Outcome Measures: 1. Cognitive performance, CERAD [ Time Frame: One assessment within 8 weeks from consent ]
    Finnish version of CERAD (Consortium to Establish a Registry for Alzheimer´s Disease). Score range: 0-100, higher score indicates a better outcome.
  • 2. Cognitive performance, MMSE [ Time Frame: One assessment within 8 weeks from consent ]
    Mini Mental State Examination. Score range: 0-30, higher score indicates a better outcome.
  • 3. Clinical Dementia Rating, units on a scale. [ Time Frame: One assessment within 8 weeks from consent ]
    Influence of cognitive impairment on the ability to conduct everyday activities on six domains (memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care). Score ranges: 0-3 (individual domain), 0-18 (total score as sum of the six domains). Lower score indicates a better outcome.
  • 4. Activity of Daily Living, Katz Index. [ Time Frame: One assessment within 8 weeks from consent ]
    Self-reported questionnaire ranking the independence in six basic daily functions. For each activity, the participant is rated either dependent (0 points) or independent (1 point). The total score score ranges 0-6 and a higher score indicates a better outcome.
  • 5. Activity of Daily Living, Lawton-Brody Scale. [ Time Frame: One assessment within 8 weeks from consent ]
    Self-reported questionnaire assessing the level of functioning in eight daily activities necessary for living in the community. For each activity, the participant is rated either dependent (0 points) or independent (1 point). Score ranges 0-8 and a higher score indicates a better outcome.
  • 6. Dementia and mild cognitive impairment [ Time Frame: Through study completion, an average of 2 years ]
    MCI and dementia diagnoses (including type of dementia) will be ascertained from the participants' medical records. Data linkage to national registers.
  • Secondary Outcome Measures: 1. Psychosocial wellbeing - Anxiety, units on a scale [ Time Frame: One assessment within 8 weeks from consent ]
    State Trait Anxiety Inventory (STAI -6), self-reported 6-item questionnaire inquiring about sense of anxiety. Score range: 0-18, a lower score indicates a better outcome.
  • 2. Physical functioning - Hand-grip strength, kg. [ Time Frame: One assessment within 8 weeks from consent ]
    The test measures the maximum isometric strength of the hand and forearm muscles and it is carried out with the aid of a hand-grip dynamometer.
  • 3. Self-reported physical activity [ Time Frame: One assessment within 8 weeks from consent ]
    Number of days/week in which physical activity is carried out for at least 20 minutes.
  • 4. Psychosocial wellbeing - Hopelessness, units on a scale. [ Time Frame: One assessment within 8 weeks from consent ]
    Self-reported questions inquiring about sense of hopelessness.
  • 5. Psychosocial wellbeing - Social network [ Time Frame: One assessment within 8 weeks from consent ]
    Self-reported questions inquiring about social network.
  • 6. Psychosocial wellbeing - Subjective memory complaints, units on a scale. [ Time Frame: One assessment within 8 weeks from consent ]
    22-item self-reported questionnaire inquiring on subjective memory. Score range: 0-66, a lower score indicates a better outcome.
  • 7. Multimorbidity [ Time Frame: Through study completion, an average of 2 years ]
    Total number of diagnoses of concomitant chronic medical conditions ascertained based on medical history data from e.g. previous follow-up data, as well as medical records. Data linkage to national registers.
  • 8. Frailty Index, units on a scale. [ Time Frame: One assessment within 8 weeks from consent ]
    Fried Frailty phenotype, defined by assessing five criteria: unintentional weight loss, self-reported exhaustion, weakness by grip strength, slow walking speed, and low physical activity. One point is attributed when each of the five criteria is met. Score range: 0-5, a lower score indicates a better outcome.
  • 9. Short Physical Performance Battery, units on a scale. [ Time Frame: One assessment within 8 weeks from consent ]
    Physical performance is assessed in three domains: balance standing (score range: 0-4), chair standing (score range: 0-4), and gait speed (score range: 0-4). The total score (range: 0-12) is the sum of the three scores. A higher score indicates a better outcome.
  • 10. Psychosocial wellbeing - Depression, units on a scale. [ Time Frame: One assessment within 8 weeks from consent ]
    Beck Depression Inventory (BDI), a 21-item self-reported questionnaire including inquiring about symptoms of depression. Score range: 0-63. A lower score indicates a better outcome.
  • 11. Psychosocial wellbeing - Life events [ Time Frame: One assessment within 8 weeks from consent ]
    Self-reported list of 12 significant life events.
  • 12. Psychosocial wellbeing - Sleep quality, units on a scale. [ Time Frame: One assessment within 8 weeks from consent ]
    Pittsburgh Sleep Quality Index (PSQI), measuring the quality and patterns of sleep in older adults. Score range 0-21. A lower score indicates a better outcome.
  • 13. Oral health [ Time Frame: One assessment within 8 weeks from consent ]
    Self-reported questions inquiring about oral health.
  • 14. Nutritional status, units on a scale. [ Time Frame: One assessment within 8 weeks from consent ]
    Mini Nutritional Assessment (MNA), a screening tool specifically designed for older adults to help identify elderly people who are malnourished or at risk of malnutrition. The assessment consists of six items evaluated by the assessor. A score (0-3 or 0-2) is attributed to each item based on the assessor's evaluation. The overall score ranges 0-14, and a higher score indicates a better outcome.
  • 15. Dietary habits [ Time Frame: One assessment within 8 weeks from consent ]
    Self-reported questions inquiring about dietary habits.
  • 16. Health-related quality of life, units on a scale. [ Time Frame: One assessment within 8 weeks from consent ]
    RAND 36-Item Health Survey 1.0, a 36-item self-reported questionnaire inquiring about health related quality of life. Score range: 0-100, a higher score indicates a better outcome.
  • Other Outcome Measures: 1. Blood pressure, mmHg. [ Time Frame: One assessment within 8 weeks from consent ]
    Systolic and diastolic blood pressure
  • 2. BMI, kg/m2 [ Time Frame: One assessment within 8 weeks from consent ]
    Body mass index
  • 3. Waist-hip ratio, cm. [ Time Frame: One assessment within 8 weeks from consent ]
    Hip-waist Circumference: measured to nearest 0.1cm
  • 4. Blood glucose, mmol/L [ Time Frame: One assessment within 8 weeks from consent ]
    Fasting Glucose
  • 5. Glycated hemoglobin, mmol/mol [ Time Frame: One assessment within 8 weeks from consent ]
    Blood level of glycated haemoglobin A1c (HbA1c)
  • 6. Cholesterol, mmol/L [ Time Frame: One assessment within 8 weeks from consent ]
    Total blood cholesterol level
  • 7. LDL cholesterol, mmol/L [ Time Frame: One assessment within 8 weeks from consent ]
    Blood low density lipoprotein cholesterol level
  • 8. HDL, mmol/L [ Time Frame: One assessment within 8 weeks from consent ]
    Blood high density lipoprotein cholesterol level
  • 9. Triglycerides, mmol/L [ Time Frame: One assessment within 8 weeks from consent ]
    Blood triglycerides level
  • 10. Creatinine, mg/dl [ Time Frame: One assessment within 8 weeks from consent ]
    Blood creatinine level
  • 11. CRP, mg/L [ Time Frame: One assessment within 8 weeks from consent ]
    Blood C-reactive protein level
  • 12. Smoking habits [ Time Frame: One assessment within 8 weeks from consent ]
    Self-reported questions about smoking status: never/past/current
  • 13. Current medications [ Time Frame: One assessment within 8 weeks from consent ]
    Self-reported list of medication currently used
  • 14. Medical history [ Time Frame: Through study completion, an average of 2 years ]
    Diagnoses, hospitalizations and other relevant events related to the participants healthcare will be recorded from national registers
  • 15. Sociodemographic factors [ Time Frame: One assessment within 8 weeks from consent ]
    Marital status, living/domicile setting, current yearly income, work history.
  • 16. Leisure activities [ Time Frame: One assessment within 8 weeks from consent ]
    Self-reported questions inquiring about 12 leisure-time activities.
Eligibility Criteria
  • Ages Eligible for Study: (Child, Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
  • Sampling Method: Probability Sample
  • Study Population: Potential participants will be selected from the original cohort of people who were invited to participate in the first CAIDE follow-up. This includes 2000 people randomly selected from the previous North Karelia and FINMONICA surverys carried out between 1972 and 1987. Any member of the original CAIDE sample still alive and living in the Kuopio or Joensuu areas (Finland) will be invited.
Criteria

Inclusion Criteria:

- Previous invitation to the first CAIDE follow up (1998)

- Being still alive and living in the Kuopio and Joensuu areas (Finland)

Exclusion Criteria:

- No exclusion criteria

Contacts and Locations
Contacts

Contact: Alina Solomon, MD, PhD 00358403552015 alina.solomon@uef.fi

Contact: Mariagnese Barbera, PhD mariagnese.barbera@uef.com

Locations

Finland
University of Eastern Finland
Kuopio

Sponsors and Collaborators

University of Eastern Finland

National Institute for Health and Welfare, Finland

Kuopio University Hospital

Investigators

Principal Investigator: Miia Kivipelto, MD, PhD University of Eastern Finland

More Information
  • Responsible Party: University of Eastern Finland
  • ClinicalTrials.gov Identifier: NCT03938727 History of Changes
  • Other Study ID Numbers: CAIDE85+
  • First Posted: May 6, 2019 Key Record Dates
  • Last Update Posted: September 6, 2019
  • Last Verified: September 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by University of Eastern Finland: Dementia
    Aging
    Alzheimer's Disease
    Cognition
    Frailty
    Epidemiology
    Lifestyle
    Cardiovascula Risk Factors
  • Additional relevant MeSH terms: Dementia